CEN Biotech (CENBF) 10-K 12 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Mar. 12, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	CEN BIOTECH INC
Entity Central Index Key	0001653821
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		27,587,363
Entity Public Float			$ 0
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(g) Security	Common Stock, No Par Value per share

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 1,908	$ 3,757
Loan receivable from Emergence Global Enterprises Inc. - related party	17,901
Total current assets	19,809	3,757
Property, plant and improvements
Property and equipment, net		148,125
Other assets
Operating lease right-of-use assets		229,284
Other receivable	113,999	424,110
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,179,328	1,065,328
Intangible assets, net	4,956,147	5,380,959
Total assets	6,314,142	7,296,422
Current liabilities
Accounts payable	190,716	181,266
Accounts payable – related parties	8,347
Loans payable	527,379	10,121,411
Loans payable – related parties	1,363,354	1,362,600
Convertible notes payable	6,652,448	5,185,412
Convertible notes payable- related parties	2,558,681	2,538,681
Accrued interest	1,125,034	9,585,055
Accrued interest – related parties	1,615,880	1,274,899
Lease liabilities	22,895	44,361
Accrued expenses	641,023	574,723
Total current liabilities	14,705,757	30,868,408
Operating lease liabilities, less current portion	142,102	184,263
Patent acquisition liability	1,380,000	720,000
Convertible notes, less current portion	78,000	1,038,913
Convertible notes - related parties, less current portion		20,000
Total liabilities	16,305,859	32,831,584
Commitments and contingencies (Notes 4, 7, 10, 11, 15, 16, 17, 19, and 21)
Shareholders’ deficit
Common stock; unlimited authorized shares; 27,557,363 and 26,953,363 issued and outstanding as of December 31, 2020 and 2019, respectively. No par value.
Additional paid-in capital	17,068,810	15,775,010
Accumulated deficit	(27,060,527)	(41,310,172)
Total shareholders’ deficit	(9,991,717)	(25,535,162)
Total liabilities and shareholders’ deficit	$ 6,314,142	$ 7,296,422

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	Dec. 31, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	27,557,363	26,953,363
Common stock, shares outstanding (in shares)	27,557,363	26,953,363

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses
Consulting fees	$ 298,077	$ 37,178
Consulting fees – related parties	124,800	154,517
Stock based compensation	746,300	1,176,600
General and administrative	1,038,466	1,211,520
Loss on lease abandonment	146,795
Loss on lease termination	2,992
Loss on disposal of property and equipment	135,600
Total operating expenses	2,543,730	2,579,815
Loss from operations	(2,543,730)	(2,579,815)
Other income (expense)
Gain on derecognition of debt and accrued interest	21,179,043
Interest expense	(3,233,421)	(2,857,910)
Interest expense – related parties	(443,437)	(449,922)
Interest income	6,400	8,252
Change in fair value of patent acquisition liability	(660,000)	290,000
Foreign exchange loss	(55,210)	(65,724)
Other income (expense), net	16,793,375	(3,075,304)
Net income (loss)	$ 14,249,645	$ (5,655,119)
Net Income (Loss) Per Share:
Basic (in dollars per share)	$ 0.52	$ (0.21)
Diluted (in dollars per share)	$ 0.45	$ (0.21)
Weighted Average Number of Shares Outstanding
Basic (in shares)	27,264,072	26,364,500
Diluted (in shares)	32,732,510	26,364,500

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2018	25,473,363
Balances at Dec. 31, 2018		$ 14,393,660	$ (35,655,053)	$ (21,261,393)
Stock-based compensation (in shares)	1,250,000
Stock-based compensation		1,176,600		1,176,600
Issuance of common stock - interest shares (in shares)	180,000
Issuance of common stock - interest shares		168,750		168,750
Issuance of common stock - consulting (in shares)	50,000
Issuance of common stock - consulting		36,000		36,000
Net income (loss)			(5,655,119)	(5,655,119)
Balances (in shares) at Dec. 31, 2019	26,953,363
Balances at Dec. 31, 2019		15,775,010	(41,310,172)	(25,535,162)
Stock-based compensation (in shares)
Stock-based compensation		746,300		746,300
Issuance of common stock - interest shares (in shares)	180,000
Issuance of common stock - interest shares		159,300		159,300
Issuance of common stock - consulting (in shares)	387,500
Issuance of common stock - consulting		279,000		279,000
Net income (loss)			14,249,645	14,249,645
Issuance of common stock - settlement of accrued liability		58,500		58,500
Issuance of common stock – lease termination settlement (in shares)	36,500
Issuance of common stock – lease termination settlement		50,700		50,700
Balances (in shares) at Dec. 31, 2020	27,557,363
Balances at Dec. 31, 2020		$ 17,068,810	$ (27,060,527)	$ (9,991,717)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net income (loss)	$ 14,249,645	$ (5,655,119)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	10,724	18,384
Amortization	424,812	424,812
Lease expense (benefit)	15,870	(660)
Loss on disposal of property and equipment	135,600
Loss on operating lease right-of-use asset - lease abandonment	146,795
Loss on operating lease right-of-use asset - lease termination settlement	2,992
Stock-based compensation - employees	746,300	1,176,600
Stock-based compensation - non-employees	279,000	36,000
Shares issued related to lease termination settlement	50,700
Shares issued for interest	159,300	168,750
Non-cash services expense	19,000
Change in fair value of patent acquisition liability	660,000	(290,000)
Gain on derecognition of debt	(21,179,043)
Foreign exchange loss	55,210	65,724
Changes in operating assets and liabilities
Other receivable	310,111	(5,205)
Accounts payable	(2,507)	(36,009)
Accounts payable – related parties	8,347
Accrued interest – related and non-related parties	3,441,595	3,055,027
Accrued expenses	124,800	172,346
Net cash used in operating activities	(340,749)	(869,350)
Cash flows from investing activities
Loan to Emergence Global Enterprises Inc.	(17,901)
Advances to CEN Biotech Ukraine LLC	(114,000)	(190,000)
Proceeds from sale of equipment	1,801
Net cash used in investing activities	(130,100)	(190,000)
Cash flows from financing activities
Issuance of convertible notes	499,000	1,045,914
Repayment of convertible notes	(30,000)	(6,000)
Issuance of convertible notes - related parties		20,000
Net cash provided by financing activities	469,000	1,059,914
Net (decrease) increase in cash and cash equivalents	(1,849)	564
Cash and cash equivalents, beginning of year	3,757	3,193
Cash and cash equivalents, end of year	1,908	3,757
Supplemental cash flows disclosures
Cash paid for interest	75,963	85,847
Non-cash transactions - investing and financing activities
Issuance of note payable for services	19,000
Issuance of common stock - settlement of accrued liability	$ 58,500

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1 NATURE OF BUSINESS CEN Biotech, Inc. (“CEN”) was incorporated in Canada on August 4, 2013 February 29, 2016, $5,807,665 January 1, 2016 The consolidated financial statements also include the accounts of Eastern Starr Biotech, Inc. (“Eastern Starr”), a Georgia corporation that was acquired on August 22, 2017 Prior to the Spin Off Distribution on February 29, 2016, March 11, 2015, CEN is focused on the manufacturing, production and development of products within the cannabis industry, including the LED lighting technology and hemp products. The Company intends to explore the usage of hemp, which it intends to cultivate for usage in industrial, medical and food products.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation CEN's consolidated financial statements include the accounts of CEN, and Eastern Starr (collectively, the “Company”). CEN Holdings' purpose was to ease and facilitate US banking transactions through March 2017. Basis of Accounting The Company's consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America. The functional currency of the Company is the U.S. dollar. Use of Estimates and Assumptions The accompanying consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and disclosure of contingent assets and liabilities at the date of the financial statements (including intangible assets), and the reported amounts of expenses during the reporting period, including stock-based compensation. Accordingly, actual results may Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three Property, Plant and Improvements Property, plant and improvements are recorded at cost. Depreciation and amortization is provided using the straight-line method over the estimated useful lives or term of the assets, which is 10 The cost of asset additions and improvements that extend the useful lives of property, plant and improvements are capitalized. Routine maintenance and repair items are charged to current operations. The original cost and accumulated depreciation of asset dispositions are removed from the accounts and any gain or loss is reflected in the statement of operations in the period of disposition. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment is performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value. If quoted market prices are not See Note 5 2020 Intangible Assets Intangible assets include a patent with a definite useful life and is being amortized over 16 may not may not Research and Development Expenditures CEN expenses all research and development expenses when incurred. There were no 2020 2019. Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities. Foreign Currency Transactions and Balances Foreign currency transactions in Canadian dollars are converted in the Company's consolidated financial statements to U.S. dollars at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are subsequently remeasured at the balance sheet date exchange rate into the functional currency. All gains and losses resulting from the settlement of foreign currency transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies are included in the consolidated statements of operations. Stock-Based Compensation The fair value of restricted stock awards granted to employees and non-employees is determined on the grant date and compensation is recognized ratably over the requisite service period equal to the fair value of the award. The Company accounts for restricted stock awards issued to employees and non-employees in accordance with the authoritative guidance in ASC Topic 718, Compensation Stock Compensation 718 718 Income (Loss) per Share Net income (loss) per common share is computed pursuant to ASC 260 10 45. 2019, not Leases The Company accounts for leases pursuant to ASC Topic 842, Leases not 2020, 20 15.

Note 3 - New Accounting Standar

Note 3 - New Accounting Standards	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	NOTE 3 NEW ACCOUNTING STANDARDS Recently Adopted Accounting Pronouncements No no 2020. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023.

Note 4 - Going Concern Uncertai

Note 4 - Going Concern Uncertainty / Management Plans	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 4 GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $27,060,527 December 31, 2020 no not not 8, 9, 10, 11. 19 no not The Company's cash position may not

Note 5 - Property, Plant and Im

Note 5 - Property, Plant and Improvements, Net	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 5 PROPERTY, PLANT AND IMPROVEMENTS, NET Property and equipment, net consists of the following as of December 31: 2020 2019 Leasehold improvements $ - $ 166,163 Furniture and equipment - 17,668 Accumulated depreciation - (35,706 ) Net property, plant and improvements $ - $ 148,125 Depreciation and amortization expense was $10,724 $18,384 December 31, 2020 2019, Effective August 1, 2020, 20 third third 15 8 $1,801 $135,600 December 31, 2020.

Note 6 - Advances to CEN Biotec

Note 6 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Advances to Related Party [Text Block]	NOTE 6 ADVANCES TO CEN BIOTECH UKRAINE AND LOAN RECEIVABLE FROM EMERGENCE GLOBAL On December 21, 2020, 14 $17,901. December 31, 2021. At December 31, 2020 2019, $1,079,328 $1,065,328 14

Note 7 - Intangible Assets

Note 7 - Intangible Assets	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 7 INTANGIBLE ASSETS On September 12, 2016, August 31, 2016, Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 135 $2,161,467 1517 1525 $202,666. The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not $200,000 In March 2018, $5 one million September 30, 2018. October 4, 2018, December 15, 2018. April 3, 2019, December 31, 2019. March 16, 2020 December 31, 2021. March 2018 $4,380,000 December 31, 2020 2019, $1,380,000 $720,000, The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no The intangible assets consists of the following as of December 31: 2020 2019 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (1,840,853 ) (1,416,041 ) Net $ 4,956,147 $ 5,380,959 As of December 31, 2020 2019, no 16 $424,812 2031, $283,215 2032.

Note 8 - Loans Payable

Note 8 - Loans Payable	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 8 LOANS PAYABLE Loans payable consist of the following at December 31: 2020 2019 Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note was previously secured by equipment that the Company disposed of on August 1, 2020. $ 75,000 $ 9,675,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000. The mortgage bears interest at 22% per annum, is unsecured, and matured on November 21, 2018. 302,379 296,411 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matures on March 16, 2021. 50,000 50,000 Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matures on March 16, 2021. 100,000 100,000 Total loans payable (all current) $ 527,379 $ 10,121,411 During 2020, $9,600,000 $11,579,043 June 30, 2016 no November 2020. 2002, 2002, 24, 2 June 30, 2016, 2 405 20 40 1 During both 2020 2019, 72,000 2020 2019, $63,720 $67,500

Note 9 - Loans Payable - Relate

Note 9 - Loans Payable - Related Party	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Loans Payable to Related Party [Text Block]	NOTE 9 LOANS PAYABLE- RELATED PARTY Loans payable - related party consists of the following at December 31: 2020 2019 Loans payable in default to the spouse of Bill Chaaban, President of CEN, for the original amounts of CAD 48,630 and USD $198,660, bear interest at 10% per annum. These are unsecured loans that matured on December 31, 2018. $ 236,854 $ 236,100 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% per annum. This are unsecured loans that matured on December 31, 2018. 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan that matured on October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban's spouse. 300,000 300,000 Loan payable to the spouse of Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matures on March 16, 2021. 100,000 100,000 Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matures on March 16, 2021. 75,000 75,000 Loan payable to Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matures on March 16, 2021. 50,000 50,000 Total loans payable - related party 1,363,354 1,362,600 Less: current portion 1,363,354 1,362,600 Long-term portion loans payable - related party $ - $ - Attributable related party accrued interest was $568,969 $460,784 December 31, 2020 2019, $202,640 $209,661 2020 2019, During both 2020 2019, 108,000 2020 2019, $95,580 $101,250

Note 10 - Convertible Notes

Note 10 - Convertible Notes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	NOTE 10 CONVERTIBLE NOTES Convertible notes payable consists of the following at December 31: 2020 2019 Convertible note payable, due on demand, for the original amount of CAD 1,104,713, bearing interest at 7% per annum with conversion rights for 335,833 common shares. $ 867,641 $ 850,519 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 3,639,365 common shares, maturing at various dates between May 2018 and September 2022. 5,862,807 5,373,806 Total convertible notes payable 6,730,448 6,224,325 Less current portion 6,652,448 5,185,412 Convertible notes payable, less current portion $ 78,000 $ 1,038,913 These notes may 3,975,198 As of March 12, 2021, $4,590,880 2,844,410

Note 11 - Convertible Notes - R

Note 11 - Convertible Notes - Related Party	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Long-term Convertible Notes Related Party [Text Block]	NOTE 11 CONVERTIBLE NOTES - RELATED PARTY Convertible notes - related party consists of the following at December 31: 2020 2019 Convertible note in default due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares and matured on August 17, 2020. $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares and matured on March 31, 2019. 878,368 878,368 Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares and matured on March 31, 2019. 48,000 48,000 Convertible notes in default due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares and matured on August 17, 2020. 224,191 224,191 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 12,500 common shares with a maturity date of June 19, 2021. 20,000 20,000 Total convertible notes payable - related party 2,558,681 2,558,681 Less current portion 2,558,681 2,538,681 Convertible notes payable - related party, less current portion $ - $ 20,000 Attributable related party accrued interest was $1,046,911 $814,115 December 31, 2020 2019, $240,797 $240,261 2020 2019, These notes may 1,599,176 As of March 12, 2021, $2,538,681 1,586,676

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 12 INCOME TAXES A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the years ended December 31: 2020 2019 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 % As of December 31, 2020, $13,000,000 may 20 2034. may not not December 31: 2020 2019 Deferred tax asset - net operating losses $ 3,400,000 $ 6,800,000 Deferred tax asset valuation allowance (3,400,000 ) (6,800,000 ) Net deferred tax asset $ - $ - The change in the valuation allowance amounted to $3,400,000 $1,500,000 December 31, 2020 2019, Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of December 31, 2020, no no no 2017.

Note 13 - Shareholders' Deficit

Note 13 - Shareholders' Deficit / Stock Activity	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 13 SHAREHOLDERS DEFICIT / STOCK ACTIVITY The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no As of December 31, 2020, 5,574,374

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 14 RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 9 11. A loan totaling $17,901 December 31, 2020. 5% July 2017 November 13, 2019. There are advances of $1,179,328 $1,065,328 December 31, 2020 2019, 6. December 3, 2017, 51% December 14, 2017, 51% not March 12, 2021, 25.5% 49% not not On July 12, 2017, 5% During the years ended December 31, 2020 2019, $124,800 $154,517, December 31, 2020 2019, $330,200 $263,900 During 2017, $300,000 $255,141 $44,859 10 2017 2026. No December 31, 2020,

Note 15 - Lease (Including Rela

Note 15 - Lease (Including Related Parties)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 15 LEASE (INCLUDING RELATED PARTIES) The Company leased 20 10.4 two one 27,000 one 53,000 4,000 4 th 2018. Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased the 20 January 2017 4,000 five third October 2019. August 1, 2020, 36,500 $50,700, August 1, 2020 $48,110 $45,118 $53,692. December 31, 2019, $68,547, $65,467, 8% 2020 2019, $20,000 $33,000, The Company also leases office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. This lease was subsequently assigned to RN Holdings Ltd, a third May 8, 2019 October 1, 2017, 2,608 September 2022, 3,390 August 1, 2020, no $146,795 August 1, 2020. March 12, 2021, not December 31, 2020 December 31, 2019, $160,737, December 31, 2020 2019 $164,997 $163,157, 8% 2020 2019, $35,000 $26,000, Maturities of the operating lease liability at December 31, 2020 Amount 2021 $ 34,822 2022 26,423 2023 31,952 2024 31,952 2025 31,952 Thereafter 55,916 Total lease payments $ 213,017 Less imputed interest 48,020 Present value of lease liabilities $ 164,997

Note 16 - Stock Based Compensat

Note 16 - Stock Based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 16 STOCK BASED COMPENSATION Adoption of Equity Compensation Plan On November 29, 2017, 2017 20,000,000 Equity Compensation Grants On November 30, 2017, one 20,000 May 20, 2019) May 21, 2019) In addition, as part of this one 1,000,000 550,000 36 1,870,000 1,330,000 36 On June 7, 2018, one 20,000 On June 19, 2018, 125,000 On December 31, 2018, 12,120 On October 1, 2019, 50,000 $36,000 On August 27, 2020 September 25, 2020, two 162,500 $117,000 Employment Agreements On November 30, 2017, four ● Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 8,750,000 7,400,000 36 November 2020. ● Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 1,250,000 325,000 36 November 2020. November 13, 2019, April 2, 2020, $58,500, 337,500 not ● Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 4,500,000 4,140,000 36 November 2020. ● Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 750,000 300,000 36 November 2020. On May 16, 2019, one one May 21, 2019 ( July 2017, In conjunction with the above, on May 16, 2019, ● Under the Employment Agreement with Alex Tarrabain, Chief Financial Officer and as one $31,200 1,250,000 350,000 36 May 2022. Restricted Stock Awards The total grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $13,013,241 $12,734,241 December 31, 2020 2019, 2020 2019, 387,500 $279,000 1,300,000 $1,298,500, three During 2020 2019, 1,987,500 1,887,500 $1,237,250 $1,380,000 2020 2019, Compensation expense, broken out by allocation, recognized in connection with the restricted stock awards was as follows for the years ended December 31: 2020 2019 Stock Based Compensation $ 746,300 $ 1,176,600 Professional fees 279,000 36,000 Total $ 1,025,300 $ 1,212,600 Non-vested restricted stock award activity for the years ended December 31, 2020 2019 Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2019 2,612,500 $ 0.62 2.00 Granted 1,300,000 1.00 - Vested (1,887,500 ) 0.70 - Forfeited - - - Non-vested at December 31, 2019 2,025,000 $ 0.76 1.54 Granted 387,500 0.72 - Vested (1,987,500 ) 0.70 - Forfeited - - - Non-vested at December 31, 2020 425,000 $ 1.01 1.50 The fair value of the restricted stock grants was based on the valuation of a third December 31, 2020, $429,250, May 2022.

Note 17 - Other Receivable

Note 17 - Other Receivable	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	NOTE 17 In May 2017, June 30, 2018 February 16, 2021, $1,000,000 $785,400 December 31, 2021 ( 2% No December 31, 2020 2019. may

Note 18 - Net Income (Loss) Per

Note 18 - Net Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 18 NET INCOME (LOSS) PER SHARE During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company's application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of December 31, 2019. 2020, 7, December 31, 2020 2019 2020 2019 Convertible debt - 4,930,555 Tesla agreement 1,000,000 1,000,000 The following table shows the computation of basic and diluted earnings per share for 2020: Income Shares Per-Share (Numerator) (Denominator) Amount Basic EPS Income available to common stockholders $ 14,249,645 27,264,072 $ 0.52 Effect of Dilutive Securities Convertible debt 585,392 5,468,438 Diluted EPS Income available to common stockholders with assumed conversions $ 14,835,037 32,732,510 $ 0.45

Note 19 - Contingency

Note 19 - Contingency	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 19 CONTINGENCY In connection with the distribution by Creative of CEN's common stock on February 29, 2016 10 May 4, 2016 5 not

Note 20 - Fair Value Disclosure

Note 20 - Fair Value Disclosures	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 20 FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company's financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2019: Cash and cash equivalents $ 3,757 $ - $ 3,757 $ - $ 3,757 Other receivables $ 424,110 $ - $ - $ 424,110 $ 424,110 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,065,328 $ - $ - $ 1,065,328 $ 1,065,328 Loans payable $ 10,121,411 $ - $ - $ 10,121,411 $ 10,121,411 Loans payable – related parties $ 1,362,600 $ - $ - $ - $ - Patent acquisition liability $ 720,000 $ - $ - $ 720,000 $ 720,000 Convertible notes payable $ 6,224,325 $ - $ - $ 6,918,486 $ 6,918,486 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - The fair values of other receivables (including related accrued interest), note receivable - related party, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability in 2020 2019 3 rd

Note 21 - Agreements and Filing

Note 21 - Agreements and Filings	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Agreements and Filings [Text Block]	NOTE 21 AGREEMENTS AND FILINGS FINRA and SEC Filings On January 27, 2020, 211 no 211 March 12, 2021, not On June 30, 2020 1 6,851,843 Termination and Release Agreement On May 19, 2020 July 31, 2018. No

Note 22 - Subsequent Events

Note 22 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 22 SUBSEQUENT EVENTS Subsequent to December 31, 2020, $110,000 68,750 Subsequent to December 31, 2020, $50,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Consolidation CEN's consolidated financial statements include the accounts of CEN, and Eastern Starr (collectively, the “Company”). CEN Holdings' purpose was to ease and facilitate US banking transactions through March 2017.
Basis of Accounting, Policy [Policy Text Block]	Basis of Accounting The Company's consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America. The functional currency of the Company is the U.S. dollar.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Assumptions The accompanying consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and disclosure of contingent assets and liabilities at the date of the financial statements (including intangible assets), and the reported amounts of expenses during the reporting period, including stock-based compensation. Accordingly, actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Improvements Property, plant and improvements are recorded at cost. Depreciation and amortization is provided using the straight-line method over the estimated useful lives or term of the assets, which is 10 The cost of asset additions and improvements that extend the useful lives of property, plant and improvements are capitalized. Routine maintenance and repair items are charged to current operations. The original cost and accumulated depreciation of asset dispositions are removed from the accounts and any gain or loss is reflected in the statement of operations in the period of disposition. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment is performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value. If quoted market prices are not See Note 5 2020
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets Intangible assets include a patent with a definite useful life and is being amortized over 16 may not may not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenditures CEN expenses all research and development expenses when incurred. There were no 2020 2019.
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Transactions and Balances Foreign currency transactions in Canadian dollars are converted in the Company's consolidated financial statements to U.S. dollars at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are subsequently remeasured at the balance sheet date exchange rate into the functional currency. All gains and losses resulting from the settlement of foreign currency transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies are included in the consolidated statements of operations.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The fair value of restricted stock awards granted to employees and non-employees is determined on the grant date and compensation is recognized ratably over the requisite service period equal to the fair value of the award. The Company accounts for restricted stock awards issued to employees and non-employees in accordance with the authoritative guidance in ASC Topic 718, Compensation Stock Compensation 718 718
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) per Share Net income (loss) per common share is computed pursuant to ASC 260 10 45. 2019, not
Lessee, Leases [Policy Text Block]	Leases The Company accounts for leases pursuant to ASC Topic 842, Leases not 2020, 20 15.

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Improvements, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	2020 2019 Leasehold improvements $ - $ 166,163 Furniture and equipment - 17,668 Accumulated depreciation - (35,706 ) Net property, plant and improvements $ - $ 148,125

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2020 2019 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (1,840,853 ) (1,416,041 ) Net $ 4,956,147 $ 5,380,959

Note 8 - Loans Payable (Tables)

Note 8 - Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Short-term Debt [Table Text Block]	2020 2019 Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note was previously secured by equipment that the Company disposed of on August 1, 2020. $ 75,000 $ 9,675,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000. The mortgage bears interest at 22% per annum, is unsecured, and matured on November 21, 2018. 302,379 296,411 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matures on March 16, 2021. 50,000 50,000 Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matures on March 16, 2021. 100,000 100,000 Total loans payable (all current) $ 527,379 $ 10,121,411

Note 9 - Loans Payable - Rela_2

Note 9 - Loans Payable - Related Party (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Loans Payable to Related Party [Table Text Block]	2020 2019 Loans payable in default to the spouse of Bill Chaaban, President of CEN, for the original amounts of CAD 48,630 and USD $198,660, bear interest at 10% per annum. These are unsecured loans that matured on December 31, 2018. $ 236,854 $ 236,100 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% per annum. This are unsecured loans that matured on December 31, 2018. 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan that matured on October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban's spouse. 300,000 300,000 Loan payable to the spouse of Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matures on March 16, 2021. 100,000 100,000 Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matures on March 16, 2021. 75,000 75,000 Loan payable to Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matures on March 16, 2021. 50,000 50,000 Total loans payable - related party 1,363,354 1,362,600 Less: current portion 1,363,354 1,362,600 Long-term portion loans payable - related party $ - $ -

Note 10 - Convertible Notes (Ta

Note 10 - Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	2020 2019 Convertible note payable, due on demand, for the original amount of CAD 1,104,713, bearing interest at 7% per annum with conversion rights for 335,833 common shares. $ 867,641 $ 850,519 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 3,639,365 common shares, maturing at various dates between May 2018 and September 2022. 5,862,807 5,373,806 Total convertible notes payable 6,730,448 6,224,325 Less current portion 6,652,448 5,185,412 Convertible notes payable, less current portion $ 78,000 $ 1,038,913

Note 11 - Convertible Notes -_2

Note 11 - Convertible Notes - Related Party (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Convertible Notes Payable to Related Party [Table Text Block]	2020 2019 Convertible note in default due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares and matured on August 17, 2020. $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares and matured on March 31, 2019. 878,368 878,368 Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares and matured on March 31, 2019. 48,000 48,000 Convertible notes in default due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares and matured on August 17, 2020. 224,191 224,191 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 12,500 common shares with a maturity date of June 19, 2021. 20,000 20,000 Total convertible notes payable - related party 2,558,681 2,558,681 Less current portion 2,558,681 2,538,681 Convertible notes payable - related party, less current portion $ - $ 20,000

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2020 2019 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2020 2019 Deferred tax asset - net operating losses $ 3,400,000 $ 6,800,000 Deferred tax asset valuation allowance (3,400,000 ) (6,800,000 ) Net deferred tax asset $ - $ -

Note 15 - Lease (Including Re_2

Note 15 - Lease (Including Related Parties) (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Amount 2021 $ 34,822 2022 26,423 2023 31,952 2024 31,952 2025 31,952 Thereafter 55,916 Total lease payments $ 213,017 Less imputed interest 48,020 Present value of lease liabilities $ 164,997

Note 16 - Stock Based Compens_2

Note 16 - Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	2020 2019 Stock Based Compensation $ 746,300 $ 1,176,600 Professional fees 279,000 36,000 Total $ 1,025,300 $ 1,212,600
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2019 2,612,500 $ 0.62 2.00 Granted 1,300,000 1.00 - Vested (1,887,500 ) 0.70 - Forfeited - - - Non-vested at December 31, 2019 2,025,000 $ 0.76 1.54 Granted 387,500 0.72 - Vested (1,987,500 ) 0.70 - Forfeited - - - Non-vested at December 31, 2020 425,000 $ 1.01 1.50

Note 18 - Net Income (Loss) P_2

Note 18 - Net Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2020 2019 Convertible debt - 4,930,555 Tesla agreement 1,000,000 1,000,000
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Income Shares Per-Share (Numerator) (Denominator) Amount Basic EPS Income available to common stockholders $ 14,249,645 27,264,072 $ 0.52 Effect of Dilutive Securities Convertible debt 585,392 5,468,438 Diluted EPS Income available to common stockholders with assumed conversions $ 14,835,037 32,732,510 $ 0.45

Note 20 - Fair Value Disclosu_2

Note 20 - Fair Value Disclosures (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2019: Cash and cash equivalents $ 3,757 $ - $ 3,757 $ - $ 3,757 Other receivables $ 424,110 $ - $ - $ 424,110 $ 424,110 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,065,328 $ - $ - $ 1,065,328 $ 1,065,328 Loans payable $ 10,121,411 $ - $ - $ 10,121,411 $ 10,121,411 Loans payable – related parties $ 1,362,600 $ - $ - $ - $ - Patent acquisition liability $ 720,000 $ - $ - $ 720,000 $ 720,000 Convertible notes payable $ 6,224,325 $ - $ - $ 6,918,486 $ 6,918,486 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ -

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details Textual) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Feb. 29, 2016
Stockholders' Equity Attributable to Parent, Ending Balance	$ (9,991,717)	$ (25,535,162)	$ (21,261,393)	$ (5,807,665)

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment, Useful Life (Year)	10 years
Finite-Lived Intangible Asset, Useful Life (Year)	16 years

Note 4 - Going Concern Uncert_2

Note 4 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (27,060,527)	$ (41,310,172)

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Improvements, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Total	$ 10,724	$ 18,384
Proceeds from Sale of Property, Plant, and Equipment, Total	1,801
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	$ (135,600)

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accumulated depreciation		$ (35,706)
Net property, plant and improvements		148,125
Leasehold Improvements [Member]
Property, plant and equipment, gross		166,163
Furniture and Equipment [Member]
Property, plant and equipment, gross		$ 17,668

Note 6 - Advances to CEN Biot_2

Note 6 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Notes Receivable, Related Parties, Current	$ 17,901
Emergence Global [Member]
Notes Receivable, Related Parties, Current	17,901
CEN Biotech Ukraine [Member]
Due from Related Parties, Total	$ 1,079,328	$ 1,065,328

Note 7 - Intangible Assets (Det

Note 7 - Intangible Assets (Details Textual) - USD ($)	Apr. 03, 2019	Sep. 12, 2016	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2020	Dec. 31, 2019
Stock Issued During Period, Value, Purchase of Assets			$ 5,000,000
Development of Acquired Technology, Annual Compensation for Specialist		$ 200,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred	$ 4,380,000
Contingent Consideration Classified as Equity, Fair Value Disclosure					$ 1,380,000	$ 720,000
Impairment of Real Estate					$ 0	$ 0
Finite-Lived Intangible Asset, Useful Life (Year)					16 years
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months					$ 424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Two					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Three					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Four					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Five					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Six					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Seven					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Eight					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Nine					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Ten					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Eleven					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Twelve					$ 283,215
Tesla Digital [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)				1,000,000
Patented Technology [Member]
Stock Issued During Period, Value, Purchase of Assets		5,000,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred		2,161,467
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred		$ 202,666

Note 7 - Intangible Assets - In

Note 7 - Intangible Assets - Intangible Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Lighting patent	$ 6,797,000	$ 6,797,000
Accumulated amortization	(1,840,853)	(1,416,041)
Net	$ 4,956,147	$ 5,380,959

Note 8 - Loans Payable (Details

Note 8 - Loans Payable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock Issued During Period, Value, New Issues	$ 159,300	$ 168,750
Individual Lenders [Member]
Stock Issued During Period, Shares, New Issues (in shares)	72,000	72,000
Stock Issued During Period, Value, New Issues	$ 63,720	$ 67,500
Global Holdings International, LLC [Member]
Derecognition of Debt, Amount	9,600,000
Derecognition of Debt, Accrued Interest, Amount	$ 11,579,043

Note 8 - Loans Payable - Loans

Note 8 - Loans Payable - Loans Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Loan payable	$ 527,379	$ 10,121,411
Short-term Loan Payable to Global Holdings International, LLC [Member]
Loan payable	75,000	9,675,000
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Loan payable	302,379	296,411
Short-term Loan Payable to an Individual [Member]
Loan payable	50,000	50,000
Second Short-term Loan Payable to an Individual [Member]
Loan payable	$ 100,000	$ 100,000

Note 8 - Loans Payable - Loan_2

Note 8 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Short-term Loan Payable to Global Holdings International, LLC [Member]
Interest Rate	15.00%	15.00%
Maturity Date	Jun. 30, 2016	Jun. 30, 2016
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Interest Rate	22.00%	22.00%
Maturity Date	Nov. 21, 2018	Nov. 21, 2018
Original Amount	$ 385,000	$ 385,000
Short-term Loan Payable to an Individual [Member]
Maturity Date	Mar. 16, 2021	Mar. 16, 2021
Share Interest (in shares)	2,000	2,000
Second Short-term Loan Payable to an Individual [Member]
Maturity Date	Mar. 16, 2021	Mar. 16, 2021
Share Interest (in shares)	4,000	4,000

Note 9 - Loans Payable - Rela_3

Note 9 - Loans Payable - Related Party (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Interest Expense, Related Party	$ 443,437	$ 449,922
Stock Issued During Period, Value, New Issues	$ 159,300	$ 168,750
Related Parties Lenders [Member]
Stock Issued During Period, Shares, New Issues (in shares)	108,000	108,000
Stock Issued During Period, Value, New Issues	$ 95,580	$ 101,250
Loans Payable to Related Party [Member]
Interest Payable, Related Party	568,969	460,784
Interest Expense, Related Party	$ 202,640	$ 209,661

Note 9 - Loans Payable-Related

Note 9 - Loans Payable-Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Long-term Debt	$ 1,363,354	$ 1,362,600
Less: current portion	1,363,354	1,362,600
Long-term portion loans payable - related party
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	236,854	236,100
Creative Edge [Member]
Long-term Debt	601,500	601,500
R&D Labs Canada, Inc [Member]
Long-term Debt	300,000	300,000
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Long-term Debt	100,000	100,000
Director, Alex Tarrabain [Member]
Long-term Debt	75,000	75,000
Joseph Byrne [Member]
Long-term Debt	$ 50,000	$ 50,000

Note 9 - Loans Payable-Relate_2

Note 9 - Loans Payable-Related Party - Loans Payable to Related Parties (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2020CAD ($)shares	Dec. 31, 2019CAD ($)shares
Director, Alex Tarrabain [Member]
Interest Rate	5.00%	5.00%	5.00%	5.00%
Maturity Date	Mar. 31, 2019	Mar. 31, 2019
Joseph Byrne [Member]
Related Party Interest	5.00%		5.00%
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	10.00%	10.00%	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | Loans Payable in Default, One [Member]
Original Amount | $			$ 48,630	$ 48,630
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | Loans Payable in Default, Two [Member]
Original Amount | $	$ 198,660	$ 198,660
Loans Payable to Related Party [Member] | Creative Edge [Member]
Interest Rate	10.00%	10.00%	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
Loans Payable to Related Party [Member] | R&D Labs Canada, Inc [Member]
Interest Rate	8.00%	8.00%	8.00%	8.00%
Maturity Date	Oct. 2, 2019	Oct. 2, 2019
Loans Payable to Related Party [Member] | Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Maturity Date	Mar. 16, 2021	Mar. 16, 2021
Share Interest (in shares)	4,000	4,000	4,000	4,000
Related Party Interest	5.00%	5.00%	5.00%	5.00%
Loans Payable to Related Party [Member] | Director, Alex Tarrabain [Member]
Maturity Date	Mar. 16, 2021	Mar. 16, 2021
Share Interest (in shares)	3,000	3,000	3,000	3,000
Loans Payable to Related Party [Member] | Joseph Byrne [Member]
Maturity Date	Mar. 16, 2021	Mar. 16, 2021
Share Interest (in shares)	2,000	2,000	2,000	2,000
Related Party Interest	5.00%	5.00%	5.00%	5.00%

Note 10 - Convertible Notes (De

Note 10 - Convertible Notes (Details Textual)	Mar. 12, 2021USD ($)	Mar. 12, 2021USD ($)	Dec. 31, 2020
Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments		68,750
Convertible Debt [Member]
Debt Instrument, Convertible, Number of Equity Instruments			3,975,198
Convertible Debt [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	2,844,410
Debt Instrument, Debt Default, Amount	$ 4,590,880	$ 4,590,880

Note 10 - Convertible Notes - C

Note 10 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Long-term Debt	$ 6,730,448	$ 6,224,325
Less: current portion	6,652,448	5,185,412
Long-term portion loans payable - related party	78,000	1,038,913
Convertible Notes 1[Member]
Long-term Debt	867,641	850,519
Convertible Notes 2 [Member]
Long-term Debt	$ 5,862,807	$ 5,373,806

Note 10 - Convertible Notes -_2

Note 10 - Convertible Notes - Convertible Notes (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)
Convertible Notes 2 [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	3,639,365	3,639,365
Maturing Dates Range Start	May 1, 2018	May 1, 2018
Maturing Dates Range End	Sep. 30, 2022	Sep. 30, 2022
Convertible Debt [Member]
Conversion Rights	3,975,198
Convertible Debt [Member] | Convertible Notes 1[Member]
Interest Rate	7.00%	7.00%
Conversion Rights	335,833	335,833
Original Amount	$ 1,104,713	$ 1,104,713

Note 11 - Convertible Notes -_3

Note 11 - Convertible Notes - Related Party (Details Textual)	Mar. 12, 2021USD ($)	Mar. 12, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Interest Expense, Related Party			$ 443,437	$ 449,922
Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments		68,750
Convertible Debt Payable to Related Party [Member]
Interest Payable, Related Party			1,046,911	814,115
Interest Expense, Related Party			$ 240,797	$ 240,261
Debt Instrument, Convertible, Number of Equity Instruments			1,599,176
Convertible Debt Payable to Related Party [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	1,586,676
Debt Instrument, Debt Default, Amount	$ 2,538,681	$ 2,538,681

Note 11 - Convertible Notes -_4

Note 11 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Long-term Debt	$ 2,558,681	$ 2,558,681
Less: current portion	2,558,681	2,538,681
Long-term portion loans payable - related party		20,000
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	1,388,122	1,388,122
Director, Harold Aubrey de Lavenu [Member]
Long-term Debt	878,368	878,368
Director, Alex Tarrabain [Member]
Long-term Debt	48,000	48,000
Joseph Byrne [Member]
Long-term Debt	224,191	224,191
Brother of Director Ameen Ferris [Member]
Long-term Debt	$ 20,000	$ 20,000

Note 11 - Convertible Notes -_5

Note 11 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Director, Alex Tarrabain [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	30,000	30,000
Maturing Dates	Mar. 31, 2019	Mar. 31, 2019
Brother of Director Ameen Ferris [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	12,500	12,500
Maturing Dates	Jun. 19, 2021	Jun. 19, 2021
Convertible Debt Payable to Related Party [Member]
Conversion Rights	1,599,176
Convertible Debt Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	867,576	867,576
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020
Convertible Debt Payable to Related Party [Member] | Director, Harold Aubrey de Lavenu [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	548,980	548,980
Maturing Dates	Mar. 31, 2019	Mar. 31, 2019
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	140,120	140,120
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards, Total	$ 13,000,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 3,400,000	$ 1,500,000

Note 12 - Income Taxes - Reconc

Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income tax benefit at Canadian statutory rate	26.50%	26.50%
Valuation allowance	(26.50%)	(26.50%)
Effective income tax rate	0.00%	0.00%

Note 12 - Income Taxes - Deferr

Note 12 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax asset - net operating losses	$ 3,400,000	$ 6,800,000
Deferred tax asset valuation allowance	(3,400,000)	(6,800,000)
Net deferred tax asset

Note 13 - Shareholders' Defic_2

Note 13 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands	Dec. 31, 2020	Dec. 31, 2019
Common Stock, No Par Value (in dollars per share)	$ 0	$ 0
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	5,574,374

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017	Dec. 14, 2017	Dec. 02, 2017	Jul. 12, 2017
Notes Receivable, Related Parties, Current	$ 17,901
Long-term Convertible Notes Payable to Multiple Private Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage						5.00%
CEN Biotech Ukraine [Member] | XN Pharma [Member]
Ownership Percentage				49.00%
CEN Biotech Ukraine [Member]
Percentage of Related Party's Equity Interest Owned by Director				25.50%
Business Acquisition, Percentage of Voting Interests Acquired				51.00%
Emergence Global [Member]
Notes Receivable, Related Parties, Current	$ 17,901
Joseph Byrne [Member]
Percentage of Related Party's Equity Interest Owned	5.00%
CEN Biotech Ukraine [Member]
Due from Related Parties, Total	$ 1,079,328	1,065,328
Percentage of Related Party's Equity Interest Owned by Director					51.00%
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings			$ 255,141
Notes Receivable, Related Parties			44,859
Board Members and Officers [Member] | Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction	124,800	154,517
Due to Related Parties, Total	$ 330,200	$ 263,900
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]
Notes Payable, Related Parties			$ 300,000

Note 15 - Lease (Including Re_3

Note 15 - Lease (Including Related Parties) (Details Textual)	Aug. 01, 2020USD ($)shares	Oct. 01, 2017CAD ($)	Sep. 30, 2022CAD ($)	Jan. 31, 2017CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2014a
Gain (Loss) on Termination of Lease					$ (2,992)
Operating Lease, Right-of-Use Asset						229,284
Operating Lease, Liability, Total					164,997
Operating Lease, Impairment Loss					146,795
Lease Arrangement, 20 North Rear Road [Member]
Area of Land (Acre) | a							10.4
Operating Lease, Monthly Rent				$ 4,000
Lessee, Operating Lease, Term of Contract (Year)				5 years
Operating Lease, Right-of-Use Asset, Write-off	$ 48,110
Operating Lease, Liability, Write off	45,118
Gain (Loss) on Termination of Lease	$ (53,692)
Operating Lease, Right-of-Use Asset						68,547
Operating Lease, Liability, Total						$ 65,467
Operating Lease, Weighted Average Discount Rate, Percent						8.00%
Lease Arrangement, 20 North Rear Road [Member] | General and Administrative Expense [Member]
Operating Lease, Expense					20,000	$ 33,000
Lease Arrangement, 20 North Rear Road [Member] | Conversion from Lease Agreement Convertible Debt to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	36,500
Debt Conversion, Converted Instrument, Amount	$ 50,700
Leases Office Space from R&D Labs Canada, Inc [Member]
Operating Lease, Monthly Rent		$ 2,608
Operating Lease, Right-of-Use Asset						160,737
Operating Lease, Liability, Total					$ 164,997	$ 163,157
Operating Lease, Weighted Average Discount Rate, Percent					8.00%	8.00%
Operating Lease, Impairment Loss	$ 146,795
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member]
Operating Lease, Monthly Rent			$ 3,390
Leases Office Space from R&D Labs Canada, Inc [Member] | General and Administrative Expense [Member]
Operating Lease, Expense					$ 35,000	$ 26,000

Note 15 - Lease (Including Re_4

Note 15 - Lease (Including Related Parties) - Future Minimum Operating Lease Payments (Details)	Dec. 31, 2020USD ($)
2021	$ 34,822
2022	26,423
2023	31,952
2024	31,952
2025	31,952
Thereafter	55,916
Total lease payments	213,017
Less imputed interest	48,020
Present value of lease liabilities	$ 164,997

Note 16 - Stock Based Compens_3

Note 16 - Stock Based Compensation (Details Textual) - USD ($)	Sep. 25, 2020	Aug. 27, 2020	Apr. 02, 2020	Oct. 01, 2019	May 16, 2019	Dec. 31, 2018	Jun. 19, 2018	Jun. 07, 2018	Nov. 30, 2017	Dec. 31, 2020	Dec. 31, 2019	Nov. 29, 2017
Common Stock, Capital Shares Reserved for Future Issuance (in shares)										5,574,374
Stock Issued During Period, Shares, Issued for Services (in shares)	162,500	162,500		50,000		12,120	125,000
Stock Issued During Period, Value, Issued for Services	$ 117,000	$ 117,000		$ 36,000						$ 279,000	$ 36,000
Chief Executive Officer [Member]
Employment Agreement, Base Annual Salary									$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									1,250,000
Accrued Salaries			$ 58,500
Number of Restricted Shares to settle Accrued Salaries (in shares)			337,500
Chief Executive Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									325,000
Vice President [Member]
Employment Agreement, Base Annual Salary									$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									750,000
Vice President [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									300,000
Senior Executive Vice President and Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary									$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									4,500,000
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									4,140,000
President [Member]
Employment Agreement, Base Annual Salary									$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									8,750,000
President [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									7,400,000
Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary					$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)					1,250,000
Chief Financial Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)					350,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	162,500	162,500								387,500	1,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)										1,987,500	1,887,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value	$ 117,000	$ 117,000								$ 279,000	$ 1,298,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value										13,013,241	12,734,241
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value										1,237,250	$ 1,380,000
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount										$ 429,250
Restricted Stock [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Vice President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Director, Alex Tarrabain [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Senior Executive Vice President and Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Director, Ameen Ferris [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,000
Restricted Stock [Member] | Director Usamakh Saadikh [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								20,000
Restricted Shares Issued for Security Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									1,870,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)									1,330,000
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)									550,000
2017 Equity Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)												20,000,000

Note 16 - Stock Based Compens_4

Note 16 - Stock Based Compensation - Compensation Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock Based Compensation [Member]
Compensation expense	$ 746,300	$ 1,176,600
Professional Fees [Member]
Compensation expense	279,000	36,000
Stock Based Compensation and Professional Fees [Member]
Compensation expense	$ 1,025,300	$ 1,212,600

Note 16 - Stock Based Compens_5

Note 16 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares	Sep. 25, 2020	Aug. 27, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-vested, number of share (in shares)			2,025,000	2,612,500
Non-vested, weighted average grant date fair value (in dollars per share)			$ 0.76	$ 0.62
Non-vested, weighted average remaining contractual term (Year)			1 year 182 days	1 year 197 days	2 years
Granted, number of share (in shares)	162,500	162,500	387,500	1,300,000
Granted, weighted average grant date fair value (in dollars per share)			$ 0.72	$ 1
Vested, number of share (in shares)			(1,987,500)	(1,887,500)
Vested, weighted average grant date fair value (in dollars per share)			$ 0.70	$ 0.70
Forfeited, number of share (in shares)
Forfeited, weighted average grant date fair value (in dollars per share)
Non-vested, number of share (in shares)			425,000	2,025,000	2,612,500
Non-vested, weighted average grant date fair value (in dollars per share)			$ 1.01	$ 0.76	$ 0.62

Note 17 - Other Receivable (Det

Note 17 - Other Receivable (Details Textual) - Line of Credit to Clear Com [Member]	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	May 31, 2017USD ($)	May 31, 2017CAD ($)
Unfunded Line of Credit Commitment, Maximum			$ 785,400	$ 1,000,000
Receivables, Interest Rate			2.00%	2.00%
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 0	$ 0

Note 18 - Net Income (Loss) P_3

Note 18 - Net Income (Loss) Per Share - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)		4,930,555
Tesla Agreement Securities [Member]
Antidilutive Securities (in shares)	1,000,000	1,000,000

Note 18 - Net Income (Loss) P_4

Note 18 - Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income available to common stockholders	$ 14,249,645
Shares, Basic (in shares)	27,264,072	26,364,500
Per share, Basic (in dollars per share)	$ 0.52	$ (0.21)
Effect of Dilutive Securities, Convertible debt	$ 585,392
Shares, Convertible debt (in shares)	5,468,438
Income available to common stockholders with assumed conversions	$ 14,835,037
Shares, Diluted (in shares)	32,732,510	26,364,500
Per share, Diluted (in dollars per share)	$ 0.45	$ (0.21)

Note 20 - Fair Value Disclosu_3

Note 20 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Reported Value Measurement [Member]
Cash and cash equivalents	$ 1,908	$ 3,757
Other receivables	113,999	424,110
Note receivable - related party	44,859	44,859
Loans payable	527,379	10,121,411
Loans payable – related parties	1,363,354	1,362,600
Patent acquisition liability	1,380,000	720,000
Convertible notes payable	6,730,448	6,224,325
Convertible notes payable – related parties	2,558,681	2,558,681
Reported Value Measurement [Member] | Emergence Global [Member]
Advances to Subsidiary	17,901
Reported Value Measurement [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	1,179,328	1,065,328
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents	1,908	3,757
Other receivables	113,999	424,110
Note receivable - related party	44,859	44,859
Loans payable	527,379	10,121,411
Loans payable – related parties
Patent acquisition liability	1,380,000	720,000
Convertible notes payable	7,766,663	6,918,486
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Emergence Global [Member]
Advances to Subsidiary	17,901
Estimate of Fair Value Measurement [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	1,179,328	1,065,328
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents
Other receivables
Note receivable - related party
Loans payable
Loans payable – related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | Emergence Global [Member]
Advances to Subsidiary
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	1,908	3,757
Other receivables
Note receivable - related party
Loans payable
Loans payable – related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | Emergence Global [Member]
Advances to Subsidiary
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Other receivables	113,999	424,110
Note receivable - related party	44,859	44,859
Loans payable	527,379	10,121,411
Loans payable – related parties
Patent acquisition liability	1,380,000	720,000
Convertible notes payable	7,766,663	6,918,486
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | Emergence Global [Member]
Advances to Subsidiary	17,901
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	$ 1,179,328	$ 1,065,328

Note 21 - Agreements and Fili_2

Note 21 - Agreements and Filings (Details Textual)	Jun. 30, 2020shares
Common Stock, Shares Authorized for Resale, Shares (in shares)	6,851,843

Note 22 - Subsequent Events (De

Note 22 - Subsequent Events (Details Textual)	2 Months Ended	12 Months Ended
	Mar. 12, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Proceeds from Convertible Debt		$ 499,000	$ 1,045,914
CEN Biotech Ukraine [Member]
Due from Related Parties, Total		$ 1,079,328	$ 1,065,328
Subsequent Event [Member]
Proceeds from Convertible Debt	$ 110,000
Debt Instrument, Convertible, Number of Equity Instruments	68,750
Subsequent Event [Member] | CEN Biotech Ukraine [Member]
Due from Related Parties, Total	$ 50,000